Shannon Heaning, Content Associate

A JAMA Dermatology study suggests higher cumulative isotretinoin doses, not higher daily doses, may help reduce acne relapse.

Roman Bronfenbrener, MD, discussed how dermatologists are using AI to streamline documentation, summarize patient records, support clinical decision-making, and improve practice operations.

The FDA accepted Arcutis' supplemental NDA seeking to expand roflumilast cream 0.05% to infants aged 3 months to younger than 2 years with mild to moderate AD.

A recent JAAD study identified a dual Th17/Type 2 immune signature in psoriasis that may help explain why biologic responses vary among patients.

Teva Pharmaceuticals will advance TEV-'408 into phase 2b after encouraging phase 1b vitiligo data showed repigmentation, favorable safety, and quarterly dosing potential.

Can-Fite completed interim enrollment for its pivotal phase 3 trial of first-in-class oral A3AR agonist piclidenoson, a potential new mechanism for plaque psoriasis.

Roman Bronfenbrener, MD, discusses how AI-generated patient diagnoses are reshaping dermatology visits and creating new challenges.

One-year phase 3 VELA data showed durable clinical responses, quality-of-life improvements, and no new safety signals for investigational sonelokimab in hidradenitis suppurativa.

AbbVie's upadacitinib received a positive CHMP opinion for severe alopecia areata as FDA review continues in the US.

A national survey examines the pressures facing independent dermatologists and strategies to strengthen practice performance.

Evommune's EVO756 failed to meet the primary end point in a phase 2b trial for chronic spontaneous urticaria, prompting the company to discontinue development for the indication while continuing studies in atopic dermatitis.